Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBIZ7H)

Drug Name
ICT-107 Drug Info
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Phase 3 [1]
Recurrent glioblastoma 2A00.00 Phase 3 [2]
Glioblastoma multiforme 2A00.0 Phase 2 [3]
Cross-matching ID
TTD Drug ID
DMBIZ7H

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Not Available [4]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Brain cancer
ICD Disease Classification 2A00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 4.40E-01 2.46 1
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 5.77E-05 4.14 2.11
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01280552) A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.